NPM1 and acute myeloid leukemia: MV4-11 represents a KMT2A-rearranged AML cell line carrying a KMT2A fusion that is typically associated with ALL and that is only sporadically detected in AML patients, and OCI-AML-3 is an NPM1-mutated AML cell line known to be sensitive to revumenib due to its exceptional dependency on menin [35].